SCHEMBL314129

SCHEMBL314129

Brc1cnc2c(c1)-n1c(nnc1-c1ccncc1)CCN2

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.41
CYP3A4 P08684 2/20 0.38
CYP11B2 P19099 2/20 0.38
CYP17A1 P05093 1/20 0.38
CYP19A1 P11511 1/20 0.38
CYP11B1 P15538 1/20 0.38
BRD4 O60885 1/20 0.34
PTK2 Q05397 1/20 0.32
CYP2C9 P11712 1/20 0.32
MAPK10 P53779 2/20 0.31
ASIC3 Q9UHC3 1/20 0.31
MAPK9 P45984 1/20 0.31
ALDH1A1 P00352 1/20 0.31
HPGD P15428 1/20 0.31
PKN1 Q16512 3/20 0.30
PKN2 Q16513 3/20 0.30
CDC7 O00311 2/20 0.30
AKT1 P31749 4/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL313799 0.91 TSHR (0.46) TSHRCYP3A4CYP11B2CYP17A1CYP19A1
SCHEMBL314776 0.85 TSHR (0.40) TSHRCYP3A4CYP11B2CYP17A1CYP19A1
SCHEMBL316222 0.64 BRD4 (0.69) TSHRCYP3A4CYP11B2CYP17A1CYP19A1
SCHEMBL1809261 0.63 BRD4 (0.46) TSHRCYP3A4CYP11B2CYP17A1CYP19A1
SCHEMBL30874428 0.62 HSD17B10 (0.33) PTK2
SCHEMBL314704 0.62 BRD4 (0.57) TSHRCYP3A4CYP11B2CYP17A1CYP19A1
SCHEMBL298258 0.62 NNMT (0.53) ASIC3
SCHEMBL10098573 0.61 BRD4 (0.50) TSHRCYP3A4CYP11B2CYP17A1CYP19A1
SCHEMBL13729796 0.59 BRD4 (0.66) TSHRCYP11B2CYP19A1CYP11B1BRD4
SCHEMBL30381675 0.58 HSD17B10 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2322527-A1 Triazole derivatives Merck Patent GmbH (DE) 2011-05-18 EP claimed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US claimed
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US disclosed
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US disclosed
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US disclosed
EP-2322527-A1 Triazole derivatives Merck Patent GmbH (DE) 2011-05-18 EP disclosed
EP-2322527-A1 Triazole derivatives Merck Patent GmbH (DE) 2011-05-18 EP disclosed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US disclosed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US disclosed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US disclosed
WO-2007079820-A1 TRIAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306042-A1 Triazole Derivatives TGFBR1, TGFBR2, SMAD3 TSHR 244/4885CYP3A4 2795/4885CYP11B2 2270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.